Increased neopterin concentrations in patients with cancer: Indicator of oxidative stress?

Anticancer Research

Volumn 19, Issue 3 A, 1999, Pages 1721-1728

  Murr, Christian ^a   Fuith, Lothar Clemens ^b   Widner, Bernhard ^a   Wirleitner, Barbara ^a   Baier Bitterlich, Gabriele ^a   Fuchs, Dietmar ^a,c  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Dept of Obstetrics and Gynecology   (Austria)

^c Institute for Medical Chemistry and Biochemistry   (Austria)

Author keywords

Cancer; Neopterin; Oxidative stress

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEOPTERIN; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; ASCITES FLUID; AUTOIMMUNE DISEASE; BLOOD LEVEL; BODY FLUID; CANCER; CANCER CELL; CANCER STAGING; CANCER SURVIVAL; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; CELLULAR IMMUNITY; GENE INDUCTION; GRAFT REJECTION; HUMAN; MACROPHAGE; MONOCYTE; ONCOGENE C FOS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SIGNAL TRANSDUCTION; URINE LEVEL; VIRUS INFECTION;

ANEMIA; BODY FLUIDS; CACHEXIA; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP CYCLOHYDROLASE; HUMANS; INFLAMMATION; INTERFERON TYPE II; NEOPLASMS; NEOPTERIN; OXIDATIVE STRESS; PTERIDINES; REACTIVE OXYGEN SPECIES; TH1 CELLS;

EID: 0032782906     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Reibnegger G, Fuchs D, Fuith LC, Hausen A, Werner ER, Werner-Felmayer G, Wachter H: Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev 15: 483490, 1991.
2. Wachter H, Fuchs D, Hausen A, Reibnegger G, Weiss G, Werner ER, Werner- elmayer G: Neopterin - Biochemistry, Methods, Clinical Application. Berlin-New York, Walter de Gruyter, 1992.
3. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H: Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon gamma. J Exp Med 160: 310-316, 1984.
4. Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, Yim JJ, Pfleiderer W, Wachter H: Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1 and T 24 cells. GPT-cyclohydrolase I is stimulated by interferon-γ, 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present. J Biol Chem 265: 3189-3192, 1990.
5. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H: Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 9: 150-155, 1988.
6. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER: Neopterin as a marker for activation of cellular immunity: Immunologic basis and clinical application. Adv Clin Chem 27: 81-141, 1989.
7. Nathan CF: Peroxide and pteridine: A hypothesis on the regulation of macrophage antimicrobial activity by interferon-γ. In: Interferon 7 (Gresser I and Vilcek J, eds). London, Academic Press, 1986, pp 125-143.
8. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H: Tumor necrosis factor-α and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe- Seyler 370: 1063-1069, 1989.
9. Brown RR, Lee CM, Kohler PC, Hank JA, Storer BE, Sondel PM: Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin-2. Cancer Res 49: 4941-4944, 1989.
10. Marth C, Weiss G, Koza A, Reibnegger G, Daxenbichler G, Zeimet AG, Fuchs D, Wachter H, Dapunt O: Increased production of immune activation marker neopterin by colony-stimulating factors in gynecological cancer patients. Int J Cancer 58: 20-23, 1994.
11. Fuchs D, Baier-Bitterlich G, Wede I, Wachter H: Reactive oxygen and apoptosis. In: Oxidative Stress and the Molecular Biology of Antioxidant Defenses (Scandalios J, ed). Cold SDrina Harbor-New York. Cold SPrina Harbor Laboratory Press. 1997. pp 139-167.
12. Fuchs D, Milstien S, Kramer A, Reibnegger G, Werner ER, Goedert JJ, Kaufman S, Wachter H: Urinary neopterin concentrations vs total neopterins for clinical utility. Clin Chem 35: 2305-2307, 1989.
13. Fuchs D, Werner ER, Wachter H: Soluble products of immune activation: neopterin. In: Manual of Clinical Laboratory Immunology (Rose NR, Conway de Macario E, Fahey JL, Friedman H and Penn GM, eds). Washington DC, American Society for Microbiology, 1992, pp 251-255.
14. Wachter H, Hausen A, Graßmayr K: Erhöhte Ausscheidung von Neopterin im Harn von Patienten mit malignen Tumoren und Viruserkrankungen. Biol Chem Hoppe-Seyler 360: 1957-1960, 1979.
15. Mura P, Piriou A, Tallineau C, Reiss D: La neopterine urinaire: Interet dans l'exploration de certaines neoplasies. Ann Biol Clin (Paris) 44: 505-510, 1986.
16. Denz H, Grunewald K, Thaler J, Huber H, Fuchs D, Hausen A, Reibnegger G, Werner ER, Wachter H: Urinary neopterin as a prognostic marker in haematological neoplasias. Pteridines 1: 167-170, 1989.
17. Reibnegger G, Krainer M, Herold M, Ludwig H, Wachter H, Hulber H: Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 51: 6250-6253, 1991.
18. Reibnegger G, Bichler A, Dapunt O, Fuchs D, Fuith LC, Hausen A, Hetzel H, Lutz H, Werner ER, Wachter H: Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res 46: 950-955, 1986.
19. Reibnegger G, Hetzel H, Fuchs D, Fuith LC, Hausen A, Wachter H: Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res 47: 4977-4981, 1987.
20. Weiss G, Kronberger P, Conrad F, Bodner E, Wachter H, Reibnegger G: Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res 53: 260-265, 1993.
21. Kronberger P, Weiss G, Tschmelitsch J, Fuchs D, Salzer GM, Wachter H, Reibnegger G: Predictive value of urinary neopterin in patients with lung cancer. Eur J Clin Chem Clin Biochem 33: 831-837, 1995.
22. Lewenhaupt A, Ekman P, Eneroth P, Eriksson A, Nilsson B, Nordstrom L: Serum levels of neopterin as related to the prognosis of human prostatic carcinoma. Eur Urol 12: 422-425, 1986.
23. Kawasaki H, Watanabe H, Yamada S, Watanabe K, Suyama A: Prognostic significance of urinary neopterin levels in patients with hepatocellular carcinoma. Tohoku J Exp Med 155: 311-318, 1988.
24. Murr C, Berchtold J, Norer B, Waldhart E, Wachter H, Fuchs D; Neopterin as a prognostic parameter in patients with squamous cell carcinomas of the oral cavity. Int J Cancer 79: 476-480, 1998.
25. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Semenitz E, Dierich MP, Wachter H: Neopterin modulates toxicity mediated by reactive oxygen and chlorine species. FEBS Lett 321: 89-92, 1993.
26. Murr C, Fuchs D, Gössler W, Hausen A, Reibnegger G, Werner ER, Werner- Felmayer G, Esterbauer H, Wachter H: Enhancement of hydrogen peroxide-induced luminol-dependent chemiluminescence by neopterin depends on the presence of iron chelator complexes. FEBS Lett 338: 223-226, 1994.
27. Heales SJR, Blair JA, Meinschad C, Ziegler I: Inhibition of monocyte luminol- dependent chemiluminescence by tetrahydrobiopterin, and the free radical oxidation of tetrahydrobiopterin, dihydrobiopterin and dihydropterin. Cell Biochem Funct 6: 191-195, 1988.
28. Wede I, Altindag ZZ, Wachter H, Fuchs D: Inhibition of xanthine oxidase by pterins. Free Radical Res 19: 331-338, 1998.
29. Kojima S, Nomura T, Icho T, Kajiwara Y, Kitabatake K, Kubota K: Inhibitory effect of neopterin on NADPH-dependent superoxide-generating oxidase of rat peritoneal macrophages. FEBS Lett 329: 125-128, 1993.
30. Baier-Bitterlich G, Fuchs D, Murr C, Reibnegger G, Werner-Felmayer G, Sgonc R, Bock G, Dierich MP, Wachter H: Effect of neopterin and 7,8-dihydroneopterin on tumor necrosis factor-a induced programmed cell death. FEBS Lett 364: 234-238, 1995.
31. 2-induced luminol chemiluminescence: mechanistic aspects. Free Radic Biol Med 21: 449-456, 1996.
32. Widner B, Baier-Bitterlich G, Wede I, Wirleitner B, Fuchs D: Neopterin derivatives modulate the nitration of tyrosine by peroxynitrite. Biochem Biophys Res Commun 248: 341-346, 1998.
33. Wede I, Semenitz E, Wachter H, Fuchs D: Neopterin and 7,8-dihydroneopterin modulate microbicidal effects of reactive oxygen and chlorine species on Escherlchia coli. Pteridines 7: 64-65, 1996.
34. Horejsi R, Estelberger W, Mlekusch W, Moller R, Öttl K, Vrecko K, Reibnegger G: Effects of pteridines on chloramine-T-induced growth inhibition in E. coli strains: correlations with molecular structure. Free Radic Biol Med 21: 133-138, 1996.
35. Baier-Bitterlich G, Fuchs D, Zangerle R, Baeuerle PA, Werner ER, Fresser F, Uberall F, Baier G, Wachter H: Transactivation of the HIV-1 promoter by 7,8-dihydroneopterin in vitro. AIDS Res Hum Retroviruses 13: 173-178, 1997.
36. Hoffmann G, Schobersberger W, Frede S, Pelzer L, Fandrey J, Wachter H, Fuchs D, Grote J: Neopterin activates transcription factor nuclear factor-kB in vascular smooth muscle cells. FEBS Lett 391: 181-184, 1996.
37. Schobersberger W, Jelkman W, Fandrey J, Frede S, Wachter H, Fuchs D: Neopterin-induced suppression of erythropoietin production in vitro. Pteridines 6: 12-16, 1995.
38. Schobersberger W, Hoffmann G, Grote J, Wachter H, Fuchs D: Induction of inducible nitric oxide synthase expression by neopterin in vascular smooth muscle cells. FEBS Lett 377: 461-464, 1995.
39. Überall F, Werner-Felmayer G, Schubert C, Grunicke HH, Wachter H, Fuchs D: Neopterin derivatives together with cyclic guanosine monophosphate induce c-fos gene expression. FEBS Lett 352: 11-14, 1994.
40. Kojitna S, Icho T, Mori H, Arai T: Enhancing potency of neopterin toward B-16 melanoma cell damage induced by UV-A irradiation and its possible application for skin tumor treatment. Anticancer Res 15: 1975-1980, 1995.
41. Schobersberger W, Hoffmann G, Hobisch-Hagen P, Bock G, Völkl H, Baier- Bitterlich G, Wirleitner B, Wachter H, Fuchs D: Neopterin and 7,8-dihydroneopterin induce apoptosis in the rat alveolar epithelial cell line L2. FEBS Lett 397: 263-268, 1996.
42. Blair JA, Pearson AJ: A kinetic study of the autooxidation of tetrahydrobiopterin. Tetrahedron Lett 3: 203-204, 1973.
43. Wirleitner B, Czaputa R, Spottl N, Widner B, Ottl K, Reibnegger G, Fuchs D, Baier-Bitterlich G. Neopterin, 7,8-dihydroneopterin und oxidativer Stress. Ber OGKC (in press).
44. Wöll E, Weiss G, Fuchs D, Lang F, Wachter H: Effect of pteridine derivatives on intracellular calcium concentration in human monocytic cells. FEBS Lett 318: 249-252, 1993.
45. Baier-Bitterlich G, Fuchs D, Wachter H: 7,8-Dihydroneopterin upregulates interferon-y promoter in T cells. Immunobiology 196: 350-355, 1996.
46. Abou Deya SH, El-Lakany SA, Sharaki OA: Advanced oxidation protein products, serum interleukin-6 and urinary neopterin as markers of cell mediated immunity in relation to proteinuria in diabetic nephropathy. Clin Chem 44 (Suppl 6): A8
47. Bos J: The ras gene family and human carcinogenesis. Mutat Res 195: 255-271, 1988.
48. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD: p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989.
49. Moraes EC, Keyse SM, Tyrell RM: Mutagenesis by hydrogen peroxide treatment of mammalian cells. Carcinogenesis 11: 283-293, 1990.
50. Dreher D, Junod AF: Differential effects of superoxide, hydrogen peroxide, and hydroxyl radical on intracellular calcium in human endothelial cells. J Cell Physiol 162: 147-153, 1995.
51. 2+]i in the induction of c-fos, cjun, and c-myc mRNA in rat PTE after oxidative stress. FASEB J. 6: 912-924, 1992.
52. Larsen R, Cerutti P: Translocation and enhancement of phosphoryltransferase activity of proteinkinase C following exposure in mouse epidermal cells to oxidants. Cancer Res 49: 5627-5632, 1989.
53. Toledano MD, Leonard WJ: Modulation of transcription factor NF-kappaB binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci USA 88: 4328-4332, 1991.
54. Buttke TM, Sandstrom PA: Oxidative stress as a mediator of apoptosis. Immunol Today 15: 7-10, 1994.
55. Dreher D, Junod AF: Role of oxygen free radicals in cancer development. Eur J Cancer 32: 30-38, 1996.
56. Cerutti PA, Trump PF: Inflammation and oxidative stress in carcinogenesis. Cancer Cells 3: 1-7, 1991.
57. Ames NB, Shigenaga MK, Hagen TM: Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci (USA) 90: 7915-7922, 1993.
58. Shu S, Plautz GE, Krauss JC, Chang AE: Tumor immunology. J Am Med Assoc 278: 1972-1981, 1997.
59. Romagnani S: Induction of Th 1 and Th 2 responses: a key role for the 'natural' immune response? Immunol Today 13: 103-108, 1992.
60. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M: Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315: 301-305, 1985.
61. Fu YX, Watson GA, Kasahara M, Lopez DM: The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma, I: induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. J Immunol 146: 783-789.
62. Black PH: Shedding from normal and cancer cell surface. N Engl J Med 303: 1415-1419, 1980.
63. Vinuela JE, Rodriguez R, Gil J, Coll J, Dela Concha EG, Subiza JL: Antigen shedding vs development of natural suppressor cells as mechanism of tumor escape in mice bearing Ehrlich tumor. Int J Cancer 47: 86-91, 1991.
64. North RJ: Down-regulation of the anti-tumor immune response. Adv Cancer Res 45: 1-43, 1985.
65. Denz H, Fuchs D, Huber H, Nachbaur D, Reibnegger G, Thaler J, Werner ER, Wachter H: Correlation between neopterin, interferon-gamma and hemoglobin in patients with haematological neoplasias. Eur J Haematol 44: 186-189, 1990.
66. Denz H, Orth B, Weiss G, Gallati H, Hermann R, Huber P, Wachter H, Fuchs D: Serum soluble tumor necrosis factor receptor 55 is increased in patients with haematological neoplasias and is associated with immune activation and weight loss. Eur J Cancer 29A: 2232-2235, 1993.
67. Fuchs D, Malkovsky M, Reibnegger G, Werner ER, Forni G, Wachter H: Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. Immunol Lett 23: 103-108, 1989/1990.
68. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D: Soluble tumor necrosis factor and neopterin as parameters of cell mediated immune activation. Eur J Haematol 54: 1-8, 1995.